Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABP2111Na
- Development stage
- Unknown
- Lead developer
- Shanghai Aibo Pharmaceutical Technology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ABP2111Na is an investigational oral small molecule drug developed by Shanghai Aibo Pharmaceutical Technology for the treatment of type 2 diabetes and obesity. It is currently being evaluated in phase 1 and phase 2 clinical trials to assess its safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy in patients with type 2 diabetes as well as overweight or obese subjects. The drug is administered orally in tablet form. While the precise mechanism of action has not been disclosed publicly, ongoing studies are focused on determining its effects on glycemic control and weight management[1][4][6].
Beyond the preview
Go deeper on ABP2111Na.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABP2111Na.